


Ask a doctor about a prescription for DURATOBAL 100 micrograms/ml INJECTABLE SOLUTION
Package Leaflet: Information for theuser
DURATOBAL 100 micrograms/ml solution for injection
Carbetocin
Read all of this leaflet carefully before you start usingthis medicine, because it contains important information for you.
Contents of the pack
The active substance of DURATOBAL is carbetocin. It is similar to a substance called oxytocin, which is produced naturally by the body to contract the uterus during childbirth.
DURATOBAL is used in the treatment of women who have just given birth.
In some women, after childbirth, the uterus (womb) does not contract quickly enough. This makes it more likely that they will bleed more than usual. DURATOBAL makes the uterus contract and thus reduces the risk of bleeding.
.
DURATOBAL should not be used until after the baby has been delivered.
Before using DURATOBAL, your doctor should know about any diseases you may have. You should tell your doctor about any new symptoms that develop while you are being treated with DURATOBAL.
Do not use DURATOBAL:
If you experience any of these symptoms, consult your doctor, midwife, or nurse.
Warnings and precautions
Tell your doctor, midwife, or nurse before receiving DURATOBAL
If you experience any of these symptoms, consult your doctor, midwife, or nurse.
DURATOBAL may cause water retention in the body, which can cause drowsiness, apathy, and headache.
Children and adolescents
Not relevant in children under 12 years.
Experience with adolescents is limited.
Using DURATOBAL with other medicines
Tell your doctor, midwife, or nurse if you are taking, have recently taken, or might take any other medicines.
Pregnancy and breastfeeding
DURATOBAL should not be used during pregnancy and childbirth until the baby has been delivered.
It has been seen that small amounts of carbetocin pass from the blood of breastfeeding mothers into breast milk, but it is assumed to be degraded in the infant's intestine. Breastfeeding does not need to be restricted after using DURATOBAL.
DURATOBAL is administered by injection into one of your veins or into one of your muscles, immediately after the delivery of your baby. The dose is one vial (100 micrograms).
If you use more DURATOBAL than you should:
If you have accidentally used more DURATOBAL than you should, you may experience uterine hyperactivity with strong contractions that can lead to uterine rupture or postpartum hemorrhage. You may also experience drowsiness, apathy, and headache caused by fluid retention. You should be treated with other medication and possible surgery.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
When DURATOBAL is administered into one of your veins after acesarean
Very common: may affect more than 1 in 10 women
Common: may affect up to 1 in 10 women
Unknown: frequency cannot be estimated from the available data
Side effects observed with similar products that may be expected with carbetocin:
Irregular heartbeats, chest pain, fainting or palpitations that may indicate that the heart is not beating correctly.
Occasionally, some women may experience sweating.
When DURATOBAL is administered into one of your muscles after a vaginal delivery
Uncommon: may affect up to 1 in 100 women
Rare: may affect less than 1 in 1,000 women
Unknown: frequency cannot be estimated from the available data
Side effects observed with similar products that may be expected with carbetocin:
Slow heart rate, irregular heartbeats, chest pain, fainting or palpitations that may indicate that the heart is not beating correctly.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use DURATOBAL after the expiry date which is stated on the carton or vial after EXP. The expiry date is the last day of the month shown.
The vials of DURATOBAL are stored in the original package to protect from light. Store below 30°C. Do not freeze.
The solution should be used immediately after opening the vial.
Composition of DURATOBAL:
The active substance is carbetocin. Each milliliter contains 100 micrograms of carbetocin.
The other ingredients are: L-methionine, succinic acid, mannitol, sodium hydroxide, and water for injection.
Appearance of DURATOBAL and contents of the pack.
Duratobal is a clear and colorless solution for injection, prepared for intravenous and intramuscular injection, and provided in packs of five 1 milliliter vials.
DURATOBAL should only be used in specialized obstetric units that are well equipped.
Marketing Authorization Holder:
FERRING S.A.U.
C/ del Arquitecto Sánchez Arcas 3, 1º
Madrid 28040
Spain
.
Manufacturer:
FERRING GMBH
Wittland 11, D-24109 Kiel
Germany
This medicine is authorized in other EEA Member States under the following names:
PABAL/ DURATOCIN.
This text was approved in June 2023
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for DURATOBAL 100 micrograms/ml INJECTABLE SOLUTION – subject to medical assessment and local rules.